8-K: Coherus Oncology Q3 2025: LOQTORZI Revenue Up, Pipeline Expands

Coherus Oncology reported increased LOQTORZI net revenue and expanded its CHS-114 clinical program to include colorectal cancer in its third quarter 2025 financial results.

Summary

• LOQTORZI net revenue for Q3 2025 was $11.2 million, marking a 12% increase over Q2 2025 and a 92% increase over Q3 2024.
• Cash, cash equivalents, and marketable securities totaled $191.7 million as of September 30, 2025, up from $126.0 million as of December 31, 2024.
• Net revenue from continuing operations for Q3 2025 was $11.6 million, compared to $6.1 million for Q3 2024.
• Net loss from continuing operations for Q3 2025 was $44.5 million, or $(0.38) per share, an improvement from a net loss of $47.6 million, or $(0.41) per share, for the same period in 2024.
• The CHS-114 CCR8 Treg depleter clinical program has been expanded to include colorectal cancer.
• Multiple data readouts are expected in 2026 across a number of tumor types for pipeline candidates.

Sentiment

Score: 7

Explanation: The company shows strong revenue growth for its key commercial product, LOQTORZI, and has expanded its clinical pipeline into new indications with multiple data readouts expected in 2026. The cash position has significantly improved. While still operating at a loss, the reduction in net loss and SG&A expenses, coupled with strategic pipeline advancements, indicates positive momentum. The impairment charge and increased R&D are noted but are part of ongoing business and development.

Positives

• LOQTORZI net revenue increased significantly to $11.2 million in Q3 2025, representing a 12% sequential increase and a 92% year-over-year increase.
• Growth in LOQTORZI revenue was driven by higher patient demand, increasing new account starts, repeat use in existing accounts, and growing average duration of treatment.
• Increased awareness of the revised National Comprehensive Cancer Network (NCCN) guidelines granting LOQTORZI preferred status within the NPC indication continues to drive strong demand growth.
• The CHS-114 clinical program was expanded to include colorectal cancer, addressing an area of growing unmet medical need.
• The company's cash, cash equivalents, and marketable securities significantly increased to $191.7 million as of September 30, 2025, from $126.0 million as of December 31, 2024.
• Net loss from continuing operations decreased to $44.5 million in Q3 2025 from $47.6 million in Q3 2024.
• Non-GAAP net loss from continuing operations decreased to $38.9 million in Q3 2025 from $40.0 million in Q3 2024.
• Selling, general and administrative (SG&A) expenses decreased due to lower headcount and reduced operating costs following recent divestitures.

Negatives

• The company continues to report a net loss from continuing operations, totaling $44.5 million in Q3 2025.
• Research and development (R&D) expenses from continuing operations increased to $27.3 million in Q3 2025 from $22.1 million in Q3 2024, primarily due to increased costs for the development of casdozokitug and CHS-114.
• A $1.6 million net impairment charge was recorded in Q3 2025 for the write-off of an intangible asset (GSK4381562) and associated contingent value right (CVR) liability.
• Market penetration for LOQTORZI in the community setting is expected to continue at a steady and gradual pace due to the rarity of NPC patients seen by general oncologists.

Risks

• Risks and uncertainties inherent in the clinical drug development process.
• Dependence on the ability to raise funds in the future, which may not be available on acceptable terms or at all.
• Risks related to existing and potential collaboration partners.
• Risks of the company's competitive position.
• Risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of regulatory filings.
• Risk of FDA review issues.
• Risks and uncertainties of possible litigation.

Future Outlook

The company expects multiple data readouts from its clinical programs throughout 2026, including initial data for CHS-114/toripalimab combinations in 2L HNSCC in 1H 2026, 1L/2L ESCC and 1L HCC in mid-2026, and 4L+ colorectal cancer in 2H 2026. Coherus plans to maximize LOQTORZI's value by combining it with internal pipeline candidates and through capital-efficient external partnerships for label expansions.

Management Comments

• "In Q3 2025, we gained significant momentum on our strategy to develop innovative oncology therapies that substantially increase patient survival." Denny Lanfear, Coherus Chairman and Chief Executive Officer.
• "The vast majority of our study sites are enrolling, driving towards multiple data readouts in 2026 across a number of tumor types." Denny Lanfear, Coherus Chairman and Chief Executive Officer.
• "We have now expanded our CHS-114 CCR8 Treg depleter clinical program to include colorectal cancer, an area of growing unmet need, impacting even younger patients." Denny Lanfear, Coherus Chairman and Chief Executive Officer.
• "The importance of CCR8 as a cancer target is highlighted by the 2025 Nobel Prize in Physiology or Medicine, which recognized the pivotal role of Treg cells in peripheral immune tolerance and their pathological role in autoimmunity and cancer." Theresa LaVallee, PhD, Coherus Chief Scientific and Development Officer.
• "Coherus Oncology was recently honored to present our clinical data on CHS-114 showing the cytolytic antibody's potency and selectively, with robust tumoral Treg depletion, immune activation and a good safety profile at a SITC presentation focused on a deep dive into development of antibodies targeting CCR8 Tregs, reflecting our scientific leadership in this rapidly evolving field." Theresa LaVallee, PhD, Coherus Chief Scientific and Development Officer.
• "Our clinical programs target tumor types where there is a clear biological rationale and a significant unmet medical need with available therapies." Rosh Dias, MD, Chief Medical Officer.
• "We have previously shown encouraging data for both casdozokitug and CHS-114, and we expect maturing datasets from our ongoing studies throughout 2026." Rosh Dias, MD, Chief Medical Officer.

Industry Context

The expansion of the CHS-114 program into colorectal cancer and the focus on Treg cells align with broader oncology trends emphasizing targeted immunotherapies and addressing unmet needs in difficult-to-treat cancers. The mention of the 2025 Nobel Prize for Treg cells underscores the scientific relevance and potential of Coherus's approach in this rapidly evolving field of cancer immunotherapy. LOQTORZI's preferred status in NCCN guidelines for NPC reflects its growing acceptance in a niche but critical oncology market.

Stakeholder Impact

• Shareholders: Potential for increased value due to growing LOQTORZI revenue, pipeline advancements, and improved cash position, but ongoing net losses and development risks remain.
• Patients: Expanded clinical programs (CHS-114 in colorectal cancer) and ongoing trials for LOQTORZI combinations and casdozokitug offer potential new treatment options for various cancers.
• Employees: Reduced headcount and lower operating costs in SG&A suggest some workforce adjustments have occurred.
• Creditors: Prepayment of term loans in 2024 and new loan facilities indicate active debt management.

Next Steps

• Present updated biomarker data for CHS-114 at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on Saturday, November 8, 2025.
• Expect initial data readouts for CHS-114/toripalimab combination dose optimization studies in 2L HNSCC in 1H 2026.
• Expect first data readout for Phase 1b study of CHS-114/toripalimab combination in 1L and 2L esophageal squamous cell carcinoma (ESCC) in mid-2026.
• Expect first data readout for Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L hepatocellular carcinoma (HCC) in mid-2026.
• Expect initial data for Phase 1b/2a study of CHS-114/toripalimab combination in 4L+ colorectal cancer in 2H 2026.
• Continue deepening LOQTORZI adoption within general oncologists in the community setting by driving education on clinical data and updated NCCN guidelines.
• Settle UDENYCA-related accrued rebates, fees, and reserves over the remainder of 2025 and into 2026.

Key Dates

Recommendation

While Coherus Oncology demonstrated strong revenue growth for LOQTORZI and made significant progress in its clinical pipeline, including expanding CHS-114 into colorectal cancer, the company continues to operate at a net loss. The improved cash position is a positive, providing runway for ongoing R&D. However, the long development timelines for oncology drugs, inherent clinical trial risks, and the gradual market penetration in the community setting for LOQTORZI suggest a 'hold' position. Investors should monitor upcoming data readouts in 2026 and further commercial traction for LOQTORZI to assess future growth potential and path to profitability.

Keywords

Coherus Oncology, CHRS, Q3 2025, Financial Results, LOQTORZI, toripalimab-tpzi, Nasopharyngeal Carcinoma, NPC, Oncology, Immunotherapy, CHS-114, CCR8 antibody, Colorectal Cancer, Casdozokitug, IL-27 antagonist, HNSCC, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, HCC, Clinical Trials, Biotechnology, Pharmaceuticals, Drug Development, SEC Filing